{"id":"NCT03885934","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU-PLAN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-25","primaryCompletion":"2020-12-09","completion":"2020-12-09","firstPosted":"2019-03-22","resultsPosted":"2021-09-23","lastUpdate":"2023-01-13"},"enrollment":606,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V114","otherNames":["Pneumococcal 15-valent Conjugate Vaccine, VAXNEUVANCE™"]},{"type":"BIOLOGICAL","name":"Prevnar 13®","otherNames":["PCV13"]}],"arms":[{"label":"V114, Schedule A: Participants 7-11 months","type":"EXPERIMENTAL"},{"label":"Prevnar 13®, Schedule A: Participants 7-11 months","type":"ACTIVE_COMPARATOR"},{"label":"V114, Schedule B: Participants 12-23 months","type":"EXPERIMENTAL"},{"label":"Prevnar 13®, Schedule B: Participants 12-23 months","type":"ACTIVE_COMPARATOR"},{"label":"V114, Schedule C: Participants 2-17 years","type":"EXPERIMENTAL"},{"label":"Prevnar 13®, Schedule C: Participants 2-17 years","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is 1) to evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events (AEs) and 2) to evaluate the anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 30 days following the last dose for each vaccination group. There is no formal hypothesis testing in this study.","primaryOutcome":{"measure":"Geometric Mean Concentration of Serotype-specific Immunoglobulin G - Schedule A: 7-11 Months","timeFrame":"30 days post last vaccination","effectByArm":[{"arm":"V114, Schedule A: Participants 7-11 Months","deltaMin":2.47,"sd":null},{"arm":"Prevnar 13®, Schedule A: Participants 7-11 Months","deltaMin":3.66,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":26,"countries":["Finland","Malaysia","Poland","Russia","Thailand"]},"refs":{"pmids":["36150974"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":64},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Irritability","Pyrexia"]}}